APMGR says that the current system will negatively impact patients and the pharmaceutical sector and the decision on a differentiated clawback tax is unjustifiably delayed.
Pharmaceutical producers say that the fiscal burden of the clawback tax became unsustainable and will trigger the drop of local generic medicine production, with social and economic effects, as many of the medicines with accessible prices will disappear from the market while the local industry will delay investments in development and will have to resort to layoffs.
APMGR includes the main generic medical drug producers in Romania: Actavis, AC Helcor, B. Braun Pharmaceuticals, Biofarm, Dr. Reddy’s, Desitin Pharma, Egis, Fresenius Kabi, Gedeon Richter, Glenmark Pharmaceuticals, Infomed Fluids, Krka, Labormed, Magistra CC, Medochemie, Sandoz, Terapia-Ranbaxy, Teva, Zentiva.